Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)

Trial Profile

An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2018

At a glance

  • Drugs Mavacamten (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Adverse reactions
  • Acronyms PIONEER-OLE
  • Sponsors MyoKardia
  • Most Recent Events

    • 30 Oct 2018 According to a MyoKardia media release, the company plans to present additional interim clinical data from this study in the first quarter of 2019, including gradient and ejection fraction data from longer term exposures, NT-proBNP and NYHA functional classification changes.
    • 30 Oct 2018 Interim twelve-week data (n=7) from this study presented in an MyoKardia media release.
    • 10 May 2018 According to a MyoKardia media release, first interim data are expected in the first quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top